Mode
Text Size
Log in / Sign up
Phase 3 N=580 Randomized Double-blind Treatment

A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

Scleroderma, Systemic

Enrolled (actual)
580
Serious AEs
29.0%
Results posted
Dec 2019
Primary outcome: Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks — -93.3; -52.4 millilitre (mL)/year (yr) — p=0.0350

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Nintedanib (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Boehringer Ingelheim
Primary completion
Oct 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks
-93.3; -52.4 0.0350 sig
SECONDARY
Absolute Change From Baseline in the Modified Rodnan Skin Score (mRSS) at Week 52
-1.96; -2.17 0.5785
SECONDARY
Absolute Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Week 52.
-0.88; 0.81 0.1711
SECONDARY
Annual Rate of Decline in FVC in Percentage (%) Predicted Over 52 Weeks
-2.6; -1.4 0.0331 sig
SECONDARY
Absolute Change From Baseline in FVC in mL at Week 52
-101.03; -54.63 0.0177 sig
SECONDARY
Relative Change From Baseline [%] of mRSS at Week 52
-3.92; -10.20 0.4547
SECONDARY
Time to Death
9; 10 0.7535
SECONDARY
The Percentage (%) of Responder Based on Combined Response Index in Systemic Sclerosis (CRISS) at Week 52
11.8; 12.2 0.9115
SECONDARY
Absolute Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco) in % Predicted at Week 52
-2.77; -3.21 0.5668
SECONDARY
Absolute Change From Baseline in Digital Ulcer Net Burden at Week 52
0.06; 0.03 0.5914
SECONDARY
Absolute Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52
0.022; 0.054 0.3447
SECONDARY
Absolute Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Dyspnoea Score at Week 52
0.34; 0.99 0.2727

Summary

Systemic Sclerosis (SSc) is a devastating disease of unknown etiology. Patients suffer from multiple organ fibrosis whereas lung fibrosis (interstitial lung disease, ILD) is one of the main driver for mortality. There is preclinical evidence for efficacy of nintedanib in SSc and associated ILD (SSc-ILD) and the anti-fibrotic efficacy of nintedanib was proven in idiopathic pulmonary fibrosis patients, who are presenting a similar pattern regarding lung fibrosis. Hence it is the purpose of the trial to confirm the efficacy and safety of nintedanib 150 mg bid in treating patients with SSc-ILD, compared with placebo. The trial will be conducted as a double blind, randomised, placebo-controlled trial with primary efficacy evaluation at week 52 and placebo-controlled treatment until last patient out (up to a maximum of 100 weeks). Respiratory function is globally accepted for assessment of treatment effects in patients with lung fibrosis. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is part of the usual examinations done in patients with SSc-ILD.

Eligibility Criteria

Inclusion criteria

  • Age >= 18 years
  • 2013 American College of Rheumatology (ACR) / EULAR classification criteria for SSc fulfilled
  • SSc disease onset (defined by first non-Raynaud symptom) within 7 years
  • SSc related Interstitial Lung Disease confirmed by High Resolution Computer Tomography (HRCT); Extent of fibrotic disease in the lung >= 10%
  • FVC >= 40% of predicted normal
  • Carbon Monoxide Diffusion Capacity (DLCO) 30% to 89% of predicted normal

Exclusion criteria

  • Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) >1.5 x ULN
  • Bilirubin >1.5 x ULN
  • Creatinine clearance 2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by >1.5 x ULN)
  • History of thrombotic event within last year
  • Clinical signs of malabsorption or needing parenteral nutrition
  • Previous treatment with nintedanib or pirfenidone
  • Treatment with prednisone >10 mg/day, azathioprine, hydroxychloroquine, colchicine, D-penicillamine, sulfasalazine, cyclophosphamide, rituximab, tocilizumab, abatacept, leflunomide, tacrolimus, newer anti-arthritic treatments like tofacitinib and cyclosporine A, potassium para-aminobenzoate
  • Unstable background therapy with either mycophenolate mofetil or methotrexate
  • Previous or planned hematopoietic stem cell transplantation
  • Patients with underlying chronic liver disease (Child Pugh A, B, C hepatic impairment)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02597933). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search